Verify dose using body surface area prior to dispensing. Recommended dosage should generally not exceed 4 mg intravenously [see OVERDOSAGE].
The recommended dose of HYCAMTIN is 1.5 mg/m² by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course.
The recommended dose of HYCAMTIN is 1.5 mg/m² by intravenous infusion over 30 minutes daily for 5 consecutive days, starting on Day 1 of a 21-day course.
The recommended dose of HYCAMTIN is 0.75 mg/m² by intravenous infusion over 30 minutes daily on Days 1, 2, and 3 in combination with cisplatin 50 mg/m² on Day 1, repeated every 21 days.
For single-agent use, dose reduce HYCAMTIN to 1.25 mg/m² for:
For combination use with cisplatin, dose reduce HYCAMTIN to 0.60 mg/m² (and further to 0.45 mg/m² if necessary) for:
For single-agent use, dose reduce HYCAMTIN to 0.75 mg/m² in patients with moderate renal impairment (creatinine clearance [Clcr] = 20 to 39 mL/min). Insufficient data are available in patients with severe renal impairment (Clcr less than 20 mL/min) to provide a dosage recommendation for HYCAMTIN [see Use in Specific Populations, CLINICAL PHARMACOLOGY].
HYCAMTIN is a cytotoxic drug. Follow applicable special handling and disposable procedures.1
Reconstitute each 4-mg vial of HYCAMTIN with 4 mL Sterile Water for Injection, USP. Dilute the appropriate volume of the reconstituted solution in either 0.9% Sodium Chloride Intravenous Infusion, USP or 5%  Dextrose in Water Injection, USP prior to administration.
Unopened vials of HYCAMTIN are stable until the date indicated on the package when stored between 20°C and 25°C (68°F and 77°F) [see USP] and protected from light in the original carton. Because the vials contain no preservative, contents should be used immediately after reconstitution.
Reconstituted vials of HYCAMTIN diluted for infusion are stable at approximately 20°C to 25°C (68°F to 77°F) and ambient lighting conditions for 24 hours.
